Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms defined by morphologic dysplasia, peripheral cytopenia, and clonal instability with enhanced risk to transform into secondary acute myeloid leukaemia (AML). The prognosis and clinical picture in MDS vary depending on the variant of disease, cell types affected and genes involved in the malignant process. In fact, more and more data suggest that cytogenetic and molecular defects and gene-variants are associated with the clinical course and prognosis. The current article provides a short summary of our knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications.